Health Claims

For people with HIV and fatty liver who are taking INSTI drugs, taking tesamorelin made their belly fat decrease by 8.3% after a year, while those on a dummy pill saw their belly fat increase by 10.8%. This finding is from the abstract summary - full study details were not available

Mitochondrial health serves as the bridge between fat loss and performance, and effective peptide stacking requires combining interventions with different mechanisms, such as tesamorelin (growth hormone/IGF-1 pathway) and MOTS-c (AMPK/mitochondrial energy sensing pathway), which act through distinct but complementary pathways to enhance mitochondrial function.

Excess visceral, liver, and intramuscular fat represent a serious metabolic dysfunction that is not solely due to lack of discipline, and reducing these fat depots improves metabolic function and overall well-being, with muscle quality being a key factor in longevity.

Tesamorelin and MOTS-c act synergistically: tesamorelin enhances fat mobilization, fat quality, and mitochondrial capacity for fat burning, while MOTS-c improves mitochondrial fuel utilization efficiency through AMPK activation, creating a complementary supply-and-utilization mechanism.

MOTS-c reduces visceral and hepatic fat and improves insulin sensitivity even on a high-fat diet by activating AMPK, the cellular energy sensor, which enhances glucose uptake, insulin signaling, and fuel efficiency.

Tesamorelin upregulates genes involved in oxidative phosphorylation across the electron transport chain and in fatty acid oxidation, leading to cellular-level metabolic remodeling that enhances fat burning efficiency at the mitochondrial level.

In a 12-month randomized, double-blind, placebo-controlled trial, tesamorelin improved mitochondrial oxidative capacity in obese adults with reduced growth hormone secretion, as measured by enhanced phosphocreatine recovery after exercise, with improvements strongly associated with increased IGF-I levels.

Tesamorelin increases muscle area and density in key trunk muscles (including rectus abdominis, psoas, spinal extensors, diaphragm, and pelvic floor) while reducing intramuscular fat infiltration, improving muscle quality and metabolic function.

Tesamorelin independently increases fat density in visceral and subcutaneous adipose tissue, indicating improved fat quality with smaller adipocytes, better vascularization, reduced hypoxia, and decreased inflammation, independent of fat quantity changes.

In a 6-month randomized, placebo-controlled trial, tesamorelin significantly reduced both visceral and hepatic (liver) fat, with liver fat reduction being particularly important as it improves insulin sensitivity and glucose metabolism.

In a 12-month randomized, double-blind, placebo-controlled trial, continued tesamorelin treatment led to an 18% reduction in visceral adipose tissue, while discontinuation resulted in rapid fat regain, demonstrating a direct and reversible cause-and-effect relationship.

In a randomized, double-blind, placebo-controlled trial of 404 HIV-infected patients with abdominal fat accumulation, tesamorelin reduced visceral adipose tissue by 10.9% (21 cm²) after 6 months compared to less than 1% in the placebo group, with concurrent reductions in waist circumference and trunk fat and increases in IGF-I levels.

Tesamorelin is a growth hormone-releasing hormone analog that stimulates the pituitary gland to produce endogenous growth hormone in a physiologically appropriate pattern, as opposed to exogenous growth hormone administration.

Visceral fat is metabolically active tissue that releases cytokines, which impair insulin sensitivity and disrupt metabolic signaling in the liver, muscles, and brain, leading to systemic metabolic dysfunction.

Visceral fat is metabolically active tissue that disrupts insulin sensitivity and metabolic function, and tesamorelin reduces it through mechanisms that improve fat quality, muscle composition, and mitochondrial efficiency, leading to long-term metabolic resilience.

Tesamorelin has robust human evidence demonstrating specific reductions in metabolically harmful fat depots including visceral, liver, and intramuscular fat.

Peptides marketed for fat loss often lack robust human evidence, relying instead on animal data or short-term biomarkers without long-term clinical validation.

After a year of treatment, tesamorelin didn't show a clear improvement in muscle energy recovery compared to a placebo in obese people with low growth hormone.

Even when accounting for factors like age, weight, and insulin levels, higher IGF-I still links to better muscle energy recovery in obese people with low growth hormone.

In obese people with low growth hormone taking tesamorelin, the link between higher IGF-I and better muscle energy recovery is even stronger than in the whole study group.

When IGF-I levels go up in obese people with low growth hormone, their muscle's ability to recover energy after exercise also improves, and this connection is statistically significant.

Taking tesamorelin for a year makes the hormone IGF-I go up much more in obese people with low growth hormone compared to taking a sugar pill.

The catalyst completely breaks down benzene gas into harmless CO2 and water, making it effective for air purification.

The electron transfer pathway keeps useful reactive particles active while reducing less useful ones, improving the catalyst's efficiency.